

Telemedicine and Remote Monitoring in Cirrhosis Care: Revolutionizing Patient Management

¹Esha S. Rithe, ²J. V. Vyas, ³Dr. V. V. Paithankar, ⁴Dr. A.M. Wankhade

Abstract:- Liver cirrhosis, a relentless and progressive liver ailment, poses distinctive challenges in patient care. The paradigm of managing cirrhotic patients has undergone a revolutionary shift with the integration of telemedicine and remote monitoring technologies in recent years. This review comprehensively examines the profound impact of these advancements on cirrhosis care, delving into their applications, benefits, and associated challenges. Telemedicine facilitates remote consultations, enabling patients to access specialized care irrespective of geographical constraints. The proactive monitoring afforded by these technologies empowers cirrhotic patients with timely interventions, fostering improved outcomes. As healthcare systems progressively adopt these innovations, cirrhotic individuals stand to gain from enhanced accessibility and a more patient-centric approach, ultimately resulting in improved health outcomes and a potential reduction in overall healthcare costs. This transformative trajectory signifies a positive shift toward comprehensive and technologically augmented cirrhosis care. This review article explores the impact of telemedicine and remote monitoring on cirrhosis care, focusing on its applications, benefits, and challenges. As healthcare systems evolve to embrace these technologies, cirrhotic patients can now receive more accessible and proactive care, ultimately improving outcomes and reducing healthcare costs.

Key Message: The integration of telemedicine and remote monitoring technologies is a significant breakthrough in the treatment of patients with liver cirrhosis, a chronic and increasingly complicated liver condition. This analysis emphasizes the transformative impact of these technologies on cirrhosis management, highlighting key takeaways for medical professionals, policymakers, and the broader healthcare community.

Keywords:- Cirrhosis, telemedicine, telecommunications, telemonitoring, virtual communications.

I. INTRODUCTION

A crippling ailment, liver cirrhosis requires lifelong care and observation. The extensive fibrosis and nodular regeneration of the liver parenchyma are hallmarks of liver cirrhosis, an irreversible and progressive condition. Cirrhosis is a result of chronic liver injury, which can have multiple etiologies, including autoimmune hepatitis, alcohol-related liver disease, viral hepatitis, and non-alcoholic fatty liver disease. It is the final stage of a liver damage continuum. Affected liver function, portal hypertension, and an increased risk of complications like ascites, hepatic encephalopathy, variceal bleeding, and hepatocellular carcinoma are caused by the disruption of the

hepatic architecture^{1,3,2}. Excessive extracellular matrix deposition is the end result of a complex pathogenesis that includes hepatocyte injury, activation of hepatic stellate cells, and inflammatory responses. To reduce complications and enhance results, cirrhosis must be identified early and managed appropriately. New developments in non-invasive diagnostic methods, like serological markers and transient elastography, help identify liver cirrhosis and fibrosis early. Treatment plans also include controlling side effects, treating the underlying cause, and, in severe cases, thinking about liver transplantation².

The treatment of cirrhosis presents a variety of difficulties, most of which are related to the disease's chronic and progressive nature. Complications from cirrhosis include hepatic encephalopathy, ascites, variceal hemorrhage, and hepatocellular carcinoma are more common in patients with the disease. To identify these issues early and launch appropriate interventions, routine monitoring is essential. However, patients may face significant challenges as a result of this requirement for regular medical evaluations, which frequently necessitates lengthy hospital stays and interferes with daily activities. Furthermore, it can be difficult for people living in rural or underdeveloped areas to get specialized care, which can cause delays in diagnosis and treatment³.

Telemedicine, as defined by the World Health Organization, involves using modern tools like telecommunications and virtual technology to deliver healthcare services remotely outside of traditional hospital settings. In the context of cirrhosis management, telemedicine and remote monitoring technologies emerge as transformative solutions⁴. By utilizing telecommunication tools, healthcare providers can conduct virtual consultations, allowing patients to receive expert guidance from a distance. This not only improves access to specialized care but also resolves logistical challenges associated with in-person visits. Additionally, remote monitoring devices enable continuous tracking of vital signs, liver function parameters, and other important clinical data from the comfort of the patient's home⁵. Real-time monitoring allows healthcare providers to promptly detect subtle changes in the patient's condition, enabling timely interventions and proactive management strategies⁶.

II. TELEMEDICINE APPLICATIONS IN CIRRHOSIS CARE

Telemedicine provides opportunities for cirrhotic patients to consult with healthcare providers remotely. This section discusses the following key applications:

A. Teleconsultations:

Teleconsultations have emerged as a valuable and essential tool in the management of cirrhosis, effectively overcoming barriers associated with geographical distance, mobility constraints, and the need for frequent in-person visits. This remote healthcare approach, particularly in the context of hepatology, plays a pivotal role in providing routine follow-ups, symptom management, and necessary adjustments to medication regimens for individuals grappling with cirrhosis.

In the realm of cirrhosis management, virtual consultations with hepatologists offer a convenient solution for patients who face challenges in regular travel to healthcare facilities, often due to the severity of their condition or other mobility issues. Through video or phone consultations, hepatologists can conduct regular follow-ups, ensuring continuous monitoring of the patient's well-being without the necessity of in-person visits. By implementing the Specialty Access Network-Extension for Community Healthcare Outcomes (SCAN-ECHO) model, the Veterans Health Administration (VA) system provides one of the most well-known telemedicine interventions: specialty consultation on case-based formats of new hepatitis C treatment options to practitioners in underserved areas⁷. Developed at the University of New Mexico, Argentina is among the countries where the ECHO model has been effectively implemented.⁸

A significant advantage of teleconsultations is their role in symptom management, a critical aspect of cirrhosis care. Patients with cirrhosis frequently contend with symptoms such as fatigue, gastrointestinal issues, and complications like hepatic encephalopathy. Through remote consultations, hepatologists can promptly assess and manage these symptoms, providing timely guidance and making necessary adjustments to the treatment plan based on the evolving symptomatology.

Additionally, teleconsultations facilitate crucial medication adjustments, contributing to the proactive management of cirrhosis. Hepatologists can remotely review medication adherence, assess the impact of prescribed drugs, and make necessary adjustments to optimize regimens. This proactive approach not only helps in mitigating potential side effects but also addresses emerging issues promptly, contributing to the overall effectiveness of the treatment plan.

Teleconsultations in cirrhosis management offer a comprehensive and patient centered approach, ensuring accessibility to healthcare and timely interventions while effectively addressing challenges associated with geographical and mobility constraints⁹.

B. Telemonitoring:

Continuous monitoring of vital signs, liver function, and medication adherence from the patient's home. Through telemonitoring, patients are observed from a distance in order to look for objective data that could inform management choices as well as signs and symptoms of the disease's progression. In the perioperative period after liver transplantation, smart tablets have been utilized in this way to monitor laboratory results, weight, and vital signs in pediatric liver transplant patients^{10,11}. Validation has been achieved for a smartphone-based Stroop test for the detection of covert hepatic encephalopathy¹². Comparably, a "Patient Buddy App" that monitors symptoms like weight gain, medication compliance, and salt intake each day has demonstrated potential in lowering hepatic encephalopathy-related hospital readmissions¹³. A novel program that employed a telehealth platform equipped with wireless blood pressure monitors, pulse oximeters, 4-G tablets, and scales proved effective in remotely monitoring patients for decompensation symptoms and indicators like bleeding, infections, hepatic encephalopathy, and fluid overload. Preventable readmissions were reduced from 33.8% in the standard of care arm to 0% in the intervention arm at 30 and 90 days. This tactic illustrated how telemonitoring can improve patient-centered care while reducing 30- and 90-day readmissions¹⁴.

C. Education and Counselling:

Education and counselling play crucial roles in the comprehensive management of chronic conditions such as cirrhosis. Telemedicine allows healthcare providers to deliver educational content to cirrhotic patients remotely. Through online platforms, patients can access resources that cover various aspects of cirrhosis, including lifestyle modifications, dietary guidelines, medication adherence, and information about potential complications. This educational outreach not only enhances patients' understanding of their condition but also equips them with the knowledge necessary for self-management¹⁵.

III. REMOTE MONITORING TECHNOLOGIES

Remote monitoring technologies are devices or applications that can measure and transmit health-related data from patients to their health care providers. They can help patients with liver cirrhosis to manage their condition, prevent complications, and improve their quality of life. Some examples of remote monitoring technologies for liver cirrhosis are:

- **Smartphone-based apps and Wearable sensors** :For many patients, the available healthcare is insufficient and dispersed. Through the use of smartphones for remote health monitoring, it is possible to identify physiological abnormalities early on, decrease hospitalizations, and enhance long-term outcomes for patients with cirrhosis who may present with predictable red flags that lead to hospitalization¹⁶.




Fig. 1: Hypothetical use of a mobile health platform for cognitive assessment in cirrhosis, leveraging technology to better diagnose and manage encephalopathy¹⁶.

Studies have suggested that smartphone-based remote monitoring may be useful for people with decompensated cirrhosis. A significant percentage of English-speaking patients receiving hepatology care at our academic centers reported using their smartphones extensively, which is defined as using all of the device's features. Smartphone users were more likely to be younger, married, jobless, live in higher-income zip codes, and have non-alcoholic cirrhosis etiology. It's interesting to note that most patients expressed

interest in smartphone-based remote health monitoring applications, irrespective of their use of smartphones or hepatic encephalopathy. Notably, a large percentage of patients did not have a spouse or long-term partner, and hepatic encephalopathy was common among smartphone users. In order to improve liver-related outcomes, these clinical and sociodemographic findings may serve as a basis for the future development of focused remote health applications for people with decompensated cirrhosis¹⁷.

Table 1: Sociodemographic Data of Decompensated Cirrhosis Patients by Smartphone Type¹⁷

	iPhone, N = 111	Android, N = 90	P value
Mean age ± SD	57.9 ± 9.9	57.4 ± 8.5	0.731
Male, %	55.9	70.0	0.042
Caucasian, %	90.9	87.8	0.642
Married, %	72.7	57.8	0.035
Long term partner relationship, %	76.4	61.1	0.022
High school diploma or higher, %	97.9 (n = 43/45)	95.6 (n = 47/48)	0.609
Not working, %	74.2	81.3	0.356
Disabled, %	23.4	40.0	0.055
Alcohol etiology, %	52.3	61.1	0.253
Hepatic encephalopathy, %	73.0	81.1	0.185
Liver transplant listed, %	34.2	33.3	0.951
Mean distance from center ± SD (miles)	47.2 ± 49.5	69.3 ± 74.6	0.017
Mean household income ± SD (USD)	108,448 ± 36,333	90,809 ± 33,007	0.0005
Interested in remote health app, %	72.6	68.7	0.603

- **Home-Based Laboratory Tests:** Tools for self-administered blood tests and the monitoring of liver function. Home-based blood tests are tests that allow people to measure their blood levels of certain biomarkers at home, using a device or a kit that collects

a small sample of blood, usually from a finger prick. The sample is then sent to a laboratory for analysis, or the device can provide instant results. Home-based blood tests can be useful for people with liver cirrhosis, as they can help them monitor their liver function and prevent

complications, without having to visit the hospital frequently.

- Some examples of home-based blood tests for liver cirrhosis are:
- **Bilirubin test:** This test quantifies the amount of bilirubin, a yellow pigment produced when red blood cells degrade. Elevations in bilirubin levels may signify harm to the liver and result in jaundice, or the yellowing of the skin and eyes. A home-based bilirubin test can use a device that measures the color of the skin, or a strip that changes color when dipped in urine¹⁸.
- **Albumin test:** This test measures the level of albumin, a protein that the liver produces. Low levels of albumin can indicate liver damage and cause fluid retention, or swelling of the legs and abdomen. A home-based albumin test can use a device that measures the electrical

conductivity of the blood, or a strip that changes colour when dipped in blood¹⁹.

- **Prothrombin time (PT) test:** The duration needed for the blood to clot is measured in this test. Clotting factors are produced by the liver and aid in halting bleeding. An elevated PT may be a sign of liver damage and raise the chance of bleeding. A home-based PT test can use a device that measures the optical density of the blood, or a strip that changes colour when dipped in blood²⁰.
- **Home-based blood tests:** can provide convenience, privacy, and cost-effectiveness for people with liver cirrhosis. However, they also have some limitations, such as accuracy, reliability, and interpretation of results. Therefore, people who use home-based blood tests should always consult their doctor before making any changes to their treatment or lifestyle²¹.




Fig. 2: Potential applications of mobile and wearable technology to detect various complications of cirrhosis²²

IV. IDEAL TELEMEDICINE APPROACH

An ideal telemedicine approach for cirrhosis management encompasses the following key elements:

- **User-Friendly Technology:** Utilize user-friendly telehealth platforms that are easily accessible to patients. The technology should be intuitive, accommodating various levels of digital literacy. This ensures a seamless experience for both healthcare providers and patients²³.
- **Remote Monitoring Devices:** Integrate remote monitoring devices for continuous tracking of vital signs and liver function. Wearable devices and home-based monitoring tools provide real-time data, enabling proactive intervention and personalized care plans.
- **Secure Communication Channels:** Prioritize secure communication channels to ensure patient data privacy. Compliance with data protection regulations and the implementation of encryption mechanisms are essential

to build trust and maintain the confidentiality of medical information .

- **Multidisciplinary Care Teams:** Establish multidisciplinary care teams involving hepatologists, nurses, dietitians, and mental health professionals. This collaborative approach ensures comprehensive care, addressing medical, nutritional, and psychosocial aspects of cirrhosis management²⁴.
- **Patient Education and Counselling:** Incorporate virtual educational resources and counselling sessions into the telemedicine framework. Providing patients with information about their condition and offering emotional support enhances their understanding and ability to manage cirrhosis effectively²⁵.
- **Integration with Electronic Health Records (EHR):** Ensure seamless integration with electronic health records for efficient information exchange between telemedicine encounters and in-person visits.

This integration promotes continuity of care and a comprehensive view of the patient's medical history²⁶.

- **The Patient Perspective on Telemedicine:** People generally accept telemedicine well. In a cross-sectional investigation involving over a million patients carried out in the J. D. Prior to the COVID-19 pandemic, telemedicine was linked to high levels of patient satisfaction even in the face of obstacles like video consultations with providers and restricted service availability. That is not to argue that issues didn't arise. More than one-third of the patients who were surveyed

reported having a problem during their visit, which left many of them feeling unsatisfied. While telemedicine can eliminate certain obstacles, like having to travel and pay for parking, it also creates new ones, like making it harder to access or understand the systems required for telehealth. There are numerous methods for getting past these obstacles. One way to help patients with telehealth is to arrange an orientation call before the telemedicine visit to make sure everyone is aware of the fees, how to pay, and what services will be rendered²⁸.



Fig. 3: Patient satisfaction with telemedicine²⁷

V. CHALLENGES AND LIMITATIONS IN THE IMPLEMENTATION OF TELEMEDICINE IN CIRRHOSIS MANAGEMENT

- **Technological Barriers** :The widespread adoption of telemedicine faces challenges related to technological barriers, particularly in terms of patient access and proficiency with technology. Disparities in the way healthcare is provided could arise from the fact that some patients may not have equal access to the required equipment or a dependable internet connection. Moreover, some patients, especially in older demographics, may lack the proficiency to navigate and effectively utilize telemedicine platforms. Addressing these issues is essential to ensure equitable access to care and the successful implementation of telemedicine in cirrhosis management²⁹.
- **Data Security:** Ensuring the privacy and security of patient data is a paramount concern in telemedicine. Emphasizes the importance of robust data security measures to safeguard patient information during remote consultations, monitoring, and interactions. Striking the right balance between accessibility and security is crucial to build trust among patients and healthcare providers. Implementing encryption, secure communication channels, and compliance with data protection regulations are essential components of a robust data security strategy in telemedicine for cirrhosis management³⁰.

- **Regulatory and Reimbursement Issues** : highlights the legal and financial considerations surrounding telemedicine, which can pose challenges to its widespread implementation. Regulatory frameworks may vary, affecting the licensure of healthcare providers delivering telemedicine services across different regions. Additionally, reimbursement policies may not be uniformly established, impacting the financial sustainability of telemedicine programs. Addressing these regulatory and reimbursement issues is critical to fostering the integration of telemedicine into mainstream healthcare practices and ensuring its viability as a long-term solution for cirrhosis management³¹.

VI. FUTURE DIRECTIONS AND CONCLUSION

Future directions in cirrhosis care involve the integration of artificial intelligence (AI) and machine learning (ML) into telemedicine and remote monitoring. These advancements promise more personalized and proactive interventions by analyzing complex datasets for early complication detection. As technology evolves, telemedicine is poised to become increasingly crucial in cirrhosis management, breaking down barriers to healthcare access. The transformative potential of these technologies is anticipated to significantly enhance patient outcomes, marking a paradigm shift towards more effective and patient-centric cirrhosis care. This review underscores the pivotal role of telemedicine and remote monitoring,

forecasting a future where technology revolutionizes the lives of cirrhotic patients. It also focus on telemedicine and remote monitoring in cirrhosis care highlights the transformative potential of these technologies in the management of this challenging condition, ultimately leading to improved patient care and outcomes.

REFERENCES

- [1]. Arroyo V, Moreau R, Kamath PS, Jalan R, Ginès P, Nevens F, Fernández J, To U, García-Tsao G, Schnabl B. Acute-on-chronic liver failure in cirrhosis. *Nature reviews Disease primers*. 2016 Jun 9;2(1):1-8.
- [2]. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. *Nature medicine*. 2018 Jul;24(7):908-22.
- [3]. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. *Hepatology*. 2017 Jan 1;65(1):310-35.
- [4]. World Health Organization. Telemedicine: opportunities and developments in member states. Report on the second global survey on eHealth. World Health Organization; 2010.
- [5]. Kalo E, Baig A, Gregg E, George J, Read S, Ma WS, Ahlenstiel G. A novel, nurse-led 'one stop' clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. *BMC gastroenterology*. 2023 Oct 16;23(1):356.
- [6]. Tapper EB, Volk M. Strategies to reduce 30-day readmissions in patients with cirrhosis. *Current gastroenterology reports*. 2017 Jan;19:1-7.
- [7]. Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, Parish B, Brown J, Komaromy M, Colleran K, Bankhurst A. Expanding access to hepatitis C virus treatment—Extension for Community Healthcare Outcomes (ECHO) project: disruptive innovation in specialty care. *Hepatology*. 2010 Sep;52(3):1124-33.
- [8]. Marciano S, Haddad L, Plazzotta F, Mauro E, Terraza S, Arora S, Thornton K, Ríos B, García Dans C, Ratusnu N, Calanni L. Implementation of the ECHO® telementoring model for the treatment of patients with hepatitis C. *Journal of medical virology*. 2017 Apr;89(4):660-4.
- [9]. Kalo E, Baig A, Gregg E, George J, Read S, Ma WS, Ahlenstiel G. A novel, nurse-led 'one stop' clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. *BMC gastroenterology*. 2023 Oct 16;23(1):356.
- [10]. Ertel AE, Kaiser TE, Abbott DE, Shah SA. Use of video-based education and tele-health home monitoring after liver transplantation: results of a novel pilot study. *Surgery*. 2016 Oct 1;160(4):869-76.
- [11]. Song B, Schulze M, Goldschmidt I, Haux R, Baumann U, Marschollek M. Home monitoring and decision support for international liver transplant children. In *MEDINFO 2013: proceedings of the 14th World Congress on Medical and Health Informatics 2013* (pp. 268-272).
- [12]. Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, Luketic V, Stravitz RT, Fuchs M, Thacker LR, Gilles H. Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy. *Clinical Gastroenterology and Hepatology*. 2015 Oct 1;13(10):1828-35.
- [13]. Ganapathy D, Acharya C, Lachar J, Patidar K, Sterling RK, White MB, Ignudo C, Bommidi S, DeSoto J, Thacker LR, Matherly S. The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. *Liver International*. 2017 Dec;37(12):1843-51.
- [14]. Khungar V, Serper M, Peyton D, Mehta S, Norris A, Hufferberger A, Siddique SM, Forde-McLean KA. Use of an innovative telehealth platform to reduce readmissions and enable patient-centered care in cirrhotic patients. In *Hepatology 2017 Oct 1* (Vol. 66, pp. 94A-95A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
- [15]. Kalo E, Baig A, Gregg E, George J, Read S, Ma WS, Ahlenstiel G. A novel, nurse-led 'one stop' clinic for patients with liver cirrhosis results in fewer liver-related unplanned readmissions and improved survival. *BMC gastroenterology*. 2023 Oct 16;23(1):356.
- [16]. Torous J, Kiang MV, Lorme J, Onnela JP. New tools for new research in psychiatry: a scalable and customizable platform to empower data driven smartphone research. *JMIR mental health*. 2016 May 5;3(2):e5165.
- [17]. Sack J, Hashemi N. Smartphone-Based Remote Health Monitoring—Implications for Healthcare Delivery in Patients with Cirrhosis. *Journal of General Internal Medicine*. 2019 Dec;34:2726-7.
- [18]. Bajaj JS, Heuman DM, Sterling RK, Sanyal AJ, Siddiqui M, Matherly S, Luketic V, Stravitz RT, Fuchs M, Thacker LR, Gilles H. Validation of EncephalApp, smartphone-based Stroop test, for the diagnosis of covert hepatic encephalopathy. *Clinical Gastroenterology and Hepatology*. 2015 Oct 1;13(10):1828-35.
- [19]. Ganapathy D, Acharya C, Lachar J, Patidar K, Sterling RK, White MB, Ignudo C, Bommidi S, DeSoto J, Thacker LR, Matherly S. The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions. *Liver International*. 2017 Dec;37(12):1843-51.
- [20]. Khungar V, Serper M, Peyton D, Mehta S, Norris A, Hufferberger A, Siddique SM, Forde-McLean KA. Use of an innovative telehealth platform to reduce readmissions and enable patient-centered care in cirrhotic patients. In *Hepatology 2017 Oct 1* (Vol. 66, pp. 94A-95A). 111 RIVER ST, HOBOKEN 07030-5774, NJ USA: WILEY.
- [21]. Sack J, Hashemi N. Smartphone-Based Remote Health Monitoring—Implications for Healthcare Delivery in Patients with Cirrhosis. *Journal of General Internal Medicine*. 2019 Dec;34:2726-7.
- [22]. Bajaj JS, Reddy KR, Tandon P, Wong F, Kamath PS, Garcia-Tsao G, Maliakkal B, Biggins SW, Thuluvath PJ, Fallon MB, Subramanian RM. The 3-month

- readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis. *Hepatology*. 2016 Jul 1;64(1):200-8.
- [24]. Whitten PS, Mackert MS. Addressing telehealth's foremost barrier: provider as initial gatekeeper. *International journal of technology assessment in health care*. 2005 Oct;21(4):517-21.
- [25]. Liu CH, Kao JH. Reply to: "Sofosbuvir and the risk of kidney dysfunction". *Journal of Hepatology*. 2021 Jan 1;74(1):257-8.
- [26]. Seo MH, Lee WY, Kim SS, Kang JH, Kang JH, Kim KK, Kim BY, Kim YH, Kim WJ, Kim EM, Kim HS. 2018 Korean society for the study of obesity guideline for the management of obesity in Korea. *Journal of obesity & metabolic syndrome*. 2019 Mar;28(1):40.
- [27]. Fisk M, Livingstone A, Pit SW. Telehealth in the context of COVID-19: changing perspectives in Australia, the United Kingdom, and the United States. *Journal of medical Internet research*. 2020 Jun 9;22(6):e19264.
- [28]. Hoyt K, Reynolds A. The patient perspective on telemedicine. *Clinical Liver Disease*. 2022 Apr;19(4):167.
- [29]. Power JD. Telehealth Patient Satisfaction Surges During Pandemic but Barriers to Access Persist. JD Power.
- [30]. Bashshur R, Shannon G, Krupinski E, Grigsby J. The taxonomy of telemedicine. *Telemedicine and e-Health*. 2011 Jul 1;17(6):484-94.
- [31]. Kang YK, Yook JH, Park YK, Kim YW, Kim J, Ryu MH, Rha SY, Chung IJ, Kim IH, Oh SC, Yoo CH. Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel (D), oxaliplatin (O) and S-1 (S)(DOS) followed by surgery and adjuvant S-1, vs surgery and adjuvant S-1, for resectable advanced gastric cancer (GC)(PRODIGY). *Annals of Oncology*. 2019 Oct 1;30:v876-7.
- [32]. Wosik J, Fudim M, Cameron B, Gellad ZF, Cho A, Phinney D, Curtis S, Roman M, Poon EG, Ferranti J, Katz JN. Telehealth transformation: COVID-19 and the rise of virtual care. *Journal of the American Medical Informatics Association*. 2020 Jun;27(6):957-62.
- [33]. O'Connell MB, Bendtsen F, Nørholm V, Brødsgaard A, Kimer N. Nurse-assisted and multidisciplinary outpatient follow-up among patients with decompensated liver cirrhosis: A systematic review. *Plos one*. 2023 Feb 9;18(2):e0278545.